Drug Profile
NN 570014
Alternative Names: NN570014Latest Information Update: 17 Jan 2008
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Succinimides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 17 Jan 2008 Discontinued - Preclinical for Type-2 diabetes mellitus in Denmark (unspecified route)
- 14 Aug 2003 No development reported - Preclinical for Type-2 diabetes mellitus in Denmark (unspecified route)
- 29 May 2001 Preclinical development for Type-2 diabetes mellitus in Denmark (Unknown route)